Drug use and opioid substitution treatment for prisoners

被引:51
|
作者
Stoever, Heino [1 ]
Michels, Ingo Ilja [2 ]
机构
[1] Univ Appl Sci, Res Inst Addict, D-60318 Frankfurt, Germany
[2] Deutsch Gesell Tech Zusammenarbeit GTZ, Cent Asia Drug Act Programme CADAP European Union, Bishkek, Kyrgyzstan
关键词
METHADONE-MAINTENANCE TREATMENT; RANDOMIZED CONTROLLED-TRIAL; HEPATITIS-C; BUPRENORPHINE; TRANSMISSION; RISK; HIV; ATTITUDES; INJECTION;
D O I
10.1186/1477-7517-7-17
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Drug use is prevalent throughout prison populations, and, despite advances in drug treatment programmes for inmates, access to and the quality of these programmes remain substantially poorer than those available for non-incarcerated drug users. Because prisoners may be at greater risk for some of the harms associated with drug use, they deserve therapeutic modalities and attitudes that are at least equal to those available for drug users outside prison. This article discusses drug use by inmates and its associated harms. In addition, this article provides a survey of studies conducted in prisons of opioid substitution therapy (OST), a clinically effective and cost-effective drug treatment strategy. The findings from this overview indicate why treatment efforts for drug users in prison are often poorer than those available for drug users in the non-prison community and demonstrate how the implementation of OST programmes benefits not only prisoners but also prison staff and the community at large. Finally, the article outlines strategies that have been found effective for implementing OST in prisons and offers suggestions for applying these strategies more broadly.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Drug use and opioid substitution treatment for prisoners
    Heino Stöver
    Ingo Ilja Michels
    Harm Reduction Journal, 7
  • [2] High variability of TB, HIV, hepatitis C treatment and opioid substitution therapy among prisoners in Germany
    Mueller, Jana
    Schmidt, Daniel
    Kollan, Christian
    Lehmann, Marc
    Bremer, Viviane
    Zimmermann, Ruth
    BMC PUBLIC HEALTH, 2017, 17 : 843
  • [3] Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities
    Johnson, Bjorn
    Richert, Torkel
    HARM REDUCTION JOURNAL, 2019, 16 (1)
  • [4] Update on pharmacotherapy for treatment of opioid use disorder
    Ayanga, Daniel
    Shorter, Daryl
    Kosten, Thomas R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (17) : 2307 - 2318
  • [5] Impact of opioid substitution therapy for Scotland's prisoners on drug-related deaths soon after prisoner release
    Bird, Sheila M.
    Fischbacher, Colin M.
    Graham, Lesley
    Fraser, Andrew
    ADDICTION, 2015, 110 (10) : 1617 - 1624
  • [6] Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment
    Nielsen, Suzanne
    Dietze, Paul
    Lee, Nicole
    Dunlop, Adrian
    Taylor, David
    ADDICTION, 2007, 102 (04) : 616 - 622
  • [7] Change in alcohol and other drug use during five years of continuous opioid substitution treatment
    Eastwood, Brian
    Strang, John
    Marsden, John
    DRUG AND ALCOHOL DEPENDENCE, 2019, 194 : 438 - 446
  • [8] Scaling up methadone maintenance treatment for opioid-dependent prisoners in Iran
    Farnia, Marziyeh
    Ebrahimi, Bahman
    Shams, Ali
    Zamani, Saman
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2010, 21 (05) : 422 - 424
  • [9] Opioid agonist treatment and the process of injection drug use initiation
    Luisa Mittal, Maria
    Jain, Sonia
    Sun, Shelly
    DeBeck, Kora
    Milloy, M. J.
    Hayashi, Kanna
    Hadland, Scott E.
    Werb, Dan
    DRUG AND ALCOHOL DEPENDENCE, 2019, 197 : 354 - 360
  • [10] Substitution treatment for opioid addicts in Germany
    Michels I.I.
    Stöver H.
    Gerlach R.
    Harm Reduction Journal, 4 (1)